Important Cautions Regarding Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

This presentation is not an offer to sell or a solicitation of an offer to purchase securities by the Company. Any such offer or solicitation, if any, will only be made by means of offering documents (e.g., prospectus, offering memorandum, subscription agreement and or similar documents) and only in jurisdictions where permitted by law. Certain information contained herein has been provided by or obtained from third-party sources and has not been independently audited or verified by the Company. The Company makes no representation or warranty, express or implied as to the accuracy or completeness of information contained in this document, and nothing contained in this document is, or shall be relied upon as, a promise or representation by the Company.

This presentation is not intended for any commercial purpose but strictly for educational or informational purposes only. Please note that some photographs and images appearing in this presentation are not necessarily those of the Company or accurate representations of its products or operations, but may be stock images, third-party operations, product mock-ups, and/or may have been edited for competitive or confidentiality reasons. Any third-party images not owned by the Company are used for non-commercial, illustrative and educational ‘fair use’ purposes only. All images and trademarks are the property of their respective owners.

© LifeMD, Inc. 2019 - 2022 All Rights Reserved.
Business Overview
A rapidly growing direct-to-patient telehealth company leveraging deep expertise in medicine, technology and marketing to make healthcare more accessible, affordable and convenient.

- 50 State Digital Pharmacy
- Nationwide Provider Network
- 600K+ Patients & Growing
- Diversified Brand Portfolio
- Proprietary Technology Platform
- Virtual Primary Care Clinic

1. # of customers that have received treatment or purchased products as of 6/30/2022.
A Differentiated Approach to Telehealth

Diversified Condition-Specific Care Strategy
Enables smarter acquisition through focused treatment offerings and precision targeting

Comprehensive Telehealth Technology Platform
Built to support an end-to-end healthcare experience and broad portfolio of treatments and services

Deep Experience in Direct-Response Marketing
Relentless focus on optimizing marketing spend, analytics and maximizing retention

Long-Term Primary Care Offering
Impacting our customers’ health by creating longitudinal patient-physician relationships
LifeMD’s Direct-to-Patient Healthcare Experience

Brand Discovery
Patient views an online or offline advertisement and visits our telehealth website.

Diagnosis/Screening
Patient is screened via online intake form and pays for treatment and medication.

Virtual Consultation
An asynchronous or audio/video consultation is conducted with the patient.

Personalized Treatment
Patient receives personalized treatment and ongoing care from the comfort of their own home.
An **End-to-End Telehealth Technology Platform**

A platform designed to accommodate a diverse portfolio of DTC telehealth offerings and primary care.

Built to handle 50 state daily consult volume at scale without sacrificing quality of care or timely service.

A mobile-first primary care platform enhanced by partnerships with Quest Diagnostics and Particle Health.

Designed with a compliance-first mindset, adhering to HIPAA standards with real-time monitoring tools.
LifeMD Simplifies Healthcare by Empowering Healthcare Providers & Patients

Cost Savings                      Condition-Specific Care
Convenience                       Primary Care
Transparency                      Prophylactic Care
Single Access Point

Proprietary Technology Platform

Empowers patients with immediacy, accessibility, and affordability.

Empowers doctors with agency, conveniency, and compliancy.

Our Digital Infrastructure Enables Scalable End-to-End Healthcare Delivery
Our Brands
Our Brands Address Large Underserved Markets

Percentage of consumers who would like a wellness visit or physical to be able to happen at home.

75%

Percentage of patients who prefer virtual visits over an in-person appointment to save time.

70%

Sources: Arizton, 2018; Medgadget, 2019; Market Research, 2020; Grand View Research, 2020; SPH Analytics, 2021
RexMD™ is a direct-to-patient telehealth brand that offers virtual healthcare for men nationwide. RexMD offers prescription medications and over-the-counter treatments for Erectile Dysfunction, Premature Ejaculation, Topical Pain Management, Hair Loss, Insomnia, Testosterone Support and more.

- 4.3 Star Trustpilot Rating
- 4+ Star Ranking on Facebook & Amazon
- Expanding Portfolio of Condition-Specific Prescription Treatments
RexMD is the third most popular ePharmacy service, following Amazon & Capsule

Source: Yahoo Omnibus, 2021
ShapiroMD® is a direct-to-patient telehealth brand that offers virtual medical treatment for male and female hair loss. ShapiroMD's product portfolio consists of a patented line of OTC products, prescription medications, and an FDA cleared medical device.

- **4.9 Star Trustpilot Rating**
- **Patent Protected and Doctor Formulated Products**
- **Robust Product Line For Both Male and Female Patients**
Cleared provides personalized treatments for allergy, asthma, and immunology including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma, and FDA-approved immunotherapies for treating chronic allergies.

- A first-in-class telehealth destination for bespoke end-to-end allergy treatment.
- Acquired by LifeMD in January 2022 to provide entry into $13.5B Allergy, Asthma and Immunology markets.
- Leading pharma partnerships; providing both B2B and B2C revenue sources.
- Highly synergistic with existing platform and accretive to Adjusted EBITDA growth.
Two of the most prevalent chronic conditions

The cost to society of allergy & asthma now exceeds $100 billion every year, and growing.

- 75M Americans suffer from allergy or asthma
- 1 in 3 U.S. adults suffer
- 115 days/year that the avg allergy sufferer experiences symptoms
- $11B annual U.S. spend on allergy/asthma medications alone
- 24M annual visits to the doctor for allergies or asthma
- $2.5B annual U.S. spend on visits to allergist

Sources: ACAAI, 2021; AAFA, 2021
NavaMD™ is a direct-to-patient telehealth brand that combines teledermatology with a patented line of clinically studied OTC skincare products. NavaMD offers virtual treatment and prescription medications for Acne, Anti-Aging, and Rosacea.

- Powered by LifeMD’s 50 State Provider Network
- Opinion Leading Dermatology Advisory Board
- $50M+ Invested in Intellectual Property & R&D

---

1. $50m+ invested by RestoreSea prior to LifeMD’s in-licensing of RestoreSea technology for NavaMD.
LifeMD is a personalized, subscription-based virtual primary care platform. The LifeMD primary care clinic provides patients access to a high-quality provider for their primary care, urgent care, and chronic care needs.

- Best-in-class virtual primary care provided by dedicated, affiliated 50-state physician network.¹
- Provide access to treatment for over 200 of the most common medical conditions.
- Affordable access to dedicated physicians starting as low as $15 per month
- Nationwide, 50 state coverage.

¹ Medical services will be furnished by a licensed medical provider practicing under our affiliated network of physician-owned professional corporations.
Financials
Early mover advantage supported by a **patient-centric approach** has enabled incredible growth

$122M-$128M
2022 Revenue Forecast

149%
YoY Revenue Growth in ‘21

600K+
Patients & Customers To-Date
Producing strong results on a sequential basis
Meaningful Improvement in Cash Burn and Bottom Line Performance; Consolidated Profitability by Q4 ‘22

Consolidated Adjusted EBITDA ($ millions)

Note: Consolidated Adjusted EBITDA includes Telehealth and WorkSimpli results.
Rapidly Accelerating Gross Margins and Increasing Leverage on Marketing Spend Driving Pathway to Profitability

Telehealth Gross Margin %

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Margin (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2021</td>
<td>68%</td>
</tr>
<tr>
<td>Q3 2021</td>
<td>70%</td>
</tr>
<tr>
<td>Q4 2021</td>
<td>72%</td>
</tr>
<tr>
<td>Q1 2022</td>
<td>74%</td>
</tr>
<tr>
<td>Q2 2022</td>
<td>76%</td>
</tr>
</tbody>
</table>

Marketing Cost as % of Sales

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Cost %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2021</td>
<td>100%</td>
</tr>
<tr>
<td>Q3 2021</td>
<td>81%</td>
</tr>
<tr>
<td>Q4 2021</td>
<td>77%</td>
</tr>
<tr>
<td>Q1 2022</td>
<td>75%</td>
</tr>
<tr>
<td>Q2 2022</td>
<td>72%</td>
</tr>
<tr>
<td>Q3 2022</td>
<td>62%</td>
</tr>
<tr>
<td>Q4 2022</td>
<td>58%</td>
</tr>
</tbody>
</table>

Note: Consolidated Net Revenue and Marketing % of Sales Telehealth and WorkSimpli
Virtual Primary Care (VPC) Has Hit Its Stride and Is Rapidly Expanding
We are **Rapidly Diversifying** from an Erectile Dysfunction (ED)-led Telehealth Provider to a Diversified Healthcare provider

![Non-ED Patient Acquisitions as % of Total Sales](chart)

- **Q2 2022**: 38%
- **Q1 2022**: 32%
- **Q4 2021**: 33%
- **Q3 2021**: 30%
- **Q2 2021**: 23%
WorkSimpli Divestiture Remains On Track

WorkSimpli Sales Process has yielded **strong demand** for the Company.

Performance of business continues to accelerate on both top-and bottom-line **driven by success across** legacy pdf business and new vertical expansion.

Process timing remains on track; targeting **closing a transaction by Q4**.
Appendix
Proven Management Team

Leadership Team of Industry Experts with a Track Record of Executing Growth Strategies

Justin Schreiber
Chief Executive Officer

Alex Mironov
President

Marc Benathen
Chief Financial Officer

Stefan Galluppi
Chief Innovation & Marketing Officer

Brad Roberts
Chief Operating Officer

Dr. Tony Puopolo
President, LifeMD Affiliated P.C.’s

Dennis Wijnker
Chief Technology Officer

Nick Alvarez
Chief Acquisition Officer

Bryant Hussey
Chief Digital Officer

Eric Yecies
General Counsel & Chief Compliance Officer
WorkSimpli, operating as WorkSimpli Software, LLC, is a rapidly growing Direct-to-Consumer document services company that is expected to provide LifeMD an ample source of liquidity.

- LifeMD owns 85.6% of WorkSimpli through a strategic investment in June 2018.
- Cloud-based Software-as-a-Service (SaaS) enables editing, converting, compressing, and splitting of PDF files.
- Users can easily edit and change text, keep PDF formatting 100% intact, and add an electronic signature for free.
- Converts Word, JPG, and PNG file formats to PDF and vice versa.
- Functions 100% online; no installation or downloads required.

- **Convert Anywhere, Anytime:** Convert PDFs to Word Doc files online from mobile or desktop.
- **100% Safe, Secure & Private:** WorkSimpli does not store customer data or information.
- **No Download or Installation:** Easy to use. Operates completely in the Cloud. Only requires an Internet connection.
Company Contact

Marc Benathen, CFO
marc@lifemd.com